News Center

Home page

Peak Report

News reports

Instructions for Amlodipine Aspartate Tablets

Release time:

2020-07-31

Approval Date: October 23, 2006
First Amendment Date: June 20, 2010
Second Amendment Date: May 05, 2015

Amlodipine Aspartate Tablets Instruction
Aspartic acid Amlodipine Tablets
Please read the instruction carefully and use

[Drug Name]
generic name under the guidance of a doctor: amlodipine aspartate tablets
trade name: liside
English name: Aspartic acid Amlodipine Tablets
Chinese pinyin: Men dong an suan an lu di ping plan-
[ingredients] the main ingredient of this product is L-amlodipine aspartate
chemical name: 2-1 [2-aminoethoxy] methyl] -4-1 (2-chlorophenyl) -1,4-dihydrogen -6-methyl pyridine -3,5-3-ethyl -5-methyl ester L-a-aspartic acid salt.
Chemical Structural Formula:

Molecular Formula: C20H25CIN205 C4H7N04
Molecular Weight: 541.99
[Character] This product is white or white-like sheet
[Indications] It can be used alone or in combination with other antihypertensive drugs to treat hypertension
[Specification] 5mg (based on amlodipine)
[Usage and Dosage] Usually the initial dose is 5mg (one sheet) once a day, but the elderly, frail, liver damage patients and patients with other antihypertensive drugs, the initial dose can be 2.5mg (half a tablet), once a day. Dosage adjustment should be based on the clinical response of the individual patient, the maximum dose can be increased to 10mg (two tablets), once a day. This product is combined with thiazide diuretics, beta blockers and angiotensin converting enzyme inhibitors without dose adjustment.
[Adverse Reactions] The more common adverse reactions are headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations and dizziness. Less common adverse reactions are angina, hypotension, bradycardia, orthostatic hypotension, pruritus, rash, dyspnea, weakness, muscle cramps, and dyspepsia. This product is similar to other calcium antagonists, there are few reports of adverse reactions of myocardial infarction and chest pain, and these adverse reactions can not be clearly distinguished from the patient's own underlying disease; no abnormal laboratory parameters related to this product have been found.
[Contraindications] Patients allergic to dihydropyridine calcium antagonists are contraindicated.
[Precautions]
L. Patients with impaired liver function: As with all other calcium blockers, the half-life of this product is prolonged when liver function is impaired, but the corresponding recommended dose has not yet been determined. Therefore, this product should be used with great care in this case.
2. Patients with renal failure: This product is widely metabolized into inactive metabolites, and only 10% of the drugs are excreted in the original form through urine. Therefore, the change of blood drug concentration is not related to the degree of renal damage. Patients with renal damage can use normal doses. This product is not dialysis.
3. This product, such as other calcium ion blockers, can rarely have gingival hyperplasia, which mostly occurs during 1-9 months of treatment, but symptoms and hyperplasia can be improved l-21 weeks after drug withdrawal.
4. There is no need to stop the drug before surgery, but the anesthesiologist must know to use this drug for treatment.
. The following conditions are prohibited:
① Severe hypotension:
② Aortic stenosis.
[Use for pregnant and lactating women] The safety of this product for pregnant and lactating women has not been established. In animal experiments, rats were given 10 mg/kg of this product. In addition to delayed delivery and prolonged labor, intrauterine death increased 5 times and the number of littermates decreased by 50%. Therefore, this product can only be used when there is no other safer alternative drug and the disease itself is more dangerous to mother and child. There are no reports on whether this product is discharged into milk.
[Children's medication] There is no information on this product for children.
[Elderly Medication] The peak time of blood drug concentration of this product is similar in elderly and young patients. The area under the curve (AUC) of elderly patients is increased, the elimination half-life is prolonged, and the clearance rate is decreased. It has been reported that older patients were as well tolerated as younger patients when receiving similar doses of amlodipine. Therefore, the elderly patients can use the normal dose, but it is advisable to start with a smaller dose, and then gradually increase the appropriate.
[Drug Interactions]
(1) Narcotics: Inhalation of hydrocarbon drugs with this product can cause hypotension.
(2) non-steroidal anti-inflammatory drugs, especially indomethacin: with this product can weaken the hypotensive effect, may be related to the inhibition of prostaglandin synthesis and (or) cause water, sodium retention.
(3) beta blockers: well tolerated with this product, but can cause excessive hypotension, rare cases can increase the possibility of congestive heart failure.
(4) Estrogen: Use with this product can increase fluid retention and increase blood pressure.
(5) Sulfopyrone (sulfinpyrazone): combined with this product can increase the protein binding rate of amlodipine and change the blood drug concentration.
(6) Lithium preparations: When used with this product, it can cause neurotoxicity, such as nausea, vomiting, diarrhea, ataxia, tremor and (or) numbness, and should be used with caution.
(7) Sympathomimetic amines may attenuate the antihypertensive effect of this product.
[Drug Overdose] Existing data suggest that severe overdose can lead to excessive dilatation of peripheral blood vessels, followed by significant and lasting systemic hypotension, bradycardia, rare II or III degree atrioventricular block, and cardiac arrest in a few patients. The former should be given intravenous dopamine, norepinephrine treatment. The latter should be given atropine, isopropyl kidney, calcium chloride treatment, if there are indications should be placed pacemaker.
[Pharmacological Toxicology]
Pharmacological Effects
This product is a calcium ion influx blocker (I. e. calcium channel blocker or calcium ion antagonist), which can selectively inhibit calcium ion from flowing into vascular smooth muscle and myocardial cells across the membrane, especially for vascular smooth muscle. This product directly dilates vascular smooth muscle, dilates peripheral arterioles, reduces peripheral resistance (afterload), and significantly dilates coronary arteries. This product has a negative inotropic effect in vivo, but has no effect on the sinoatrial node and atrioventricular node.
Toxicological Study
Acute Toxicity in Mice: The LD 50 of L-aspartate amlodipine bulk drug administered by gavage is 80.2 mg/kg(95% confidence limit is 71.3-90.2 mg/kg); The LD 50 for intraperitoneal injection is 62.1 mg/kg(95% confidence limit is 55.0-70.1 mg/kg).
Genotoxicity: Mutagenicity test results indicate no drug-related gene or chromosome level mutagenicity.
Reproductive toxicity: General reproductive toxicity test, oral administration of amlodipine 10 mg/kg/day (based on body surface area, about 8 times the maximum recommended human dose of lOmg) to rats has no damage to fertility. Oral administration of 10 mg/kg of amlodipine (about 8 times and 23 times the maximum recommended human dose of 10mg in terms of body surface area, respectively) to pregnant rats and rabbits during organogenesis had no teratogenic effect on embryos. However, oral administration of amlodipine 10 mg/kg 14 days before mating and pregnancy in rats significantly reduced the number of littermates (about 50%), increased intrauterine mortality (about 5 times), and prolonged pregnancy and labor. Adequate and well-controlled trials have not been conducted in pregnant women, so pregnant women should only take this product during pregnancy when their potential benefits are large and potentially dangerous to the fetus.
It is not clear whether this product is excreted in human milk. In view of the lack of information in this regard, it is recommended to stop using it during lactation.
Carcinogenicity: Amlodipine is carcinogenic in rats and mice for two years. Mixed food doses of 0.5,1.25, and 2.5 mg/kg/day are non-carcinogenic. The highest dose (calculated by body surface area, the mouse dose is equivalent to the maximum recommended clinical dose of 10mg, while the rat dose is twice) is close to the maximum tolerance of mice.
[Pharmacokinetics] It is reported in the literature that this product is well absorbed orally and is not affected by food intake. The plasma protein binding rate is about 97.5, the blood drug concentration reaches the peak value 6-12 hours after single administration, the absolute bioavailability is about 64-80%, the apparent distribution volume is about 21L/kg, the final elimination half-life is about 35-50 hours, once a day, after 7-8 days of continuous administration, blood drug concentration reached steady state. This product is widely metabolized by the liver into inactive metabolites, 10% of which are excreted as original drugs and 60% as metabolites through urine.
【Storage】 Shaded, sealed and stored in a dry place..
【Packing】 Aluminum-plastic plate packaging, each small carton containing seven or fourteen pieces.
[Validity] 24 months.
[Implementation Standard] WS-(X-101)-2005Z
[Approval Document No.] Guoyao Zhun Zi H20020487
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax

:

More information

Jianfeng International Trade Selected as Pilot Enterprise of Non-car Carrier Logistics

In August, Jianfeng International Trading Company successfully passed the evaluation of traffic management departments and expert groups in Zhejiang Province and Jinhua City, and was successfully selected as a pilot enterprise of car-free carrier logistics in Zhejiang Province in 2019. "Car-free transportation" is a new format in the logistics industry brought about by the widespread application of information Internet technology. The "car-free carrier" signs a transportation contract with the shipper as a carrier, assumes the responsibilities and obligations of the carrier, and entrusts the actual carrier to complete the transportation task. Road freight operators. Compared with the traditional concept of logistics mode, car free carrier has the characteristics of strong resource integration ability, wide brand effect and obvious network effect. It is of great significance to promote the intensive integration of resources and the standardized development of the freight market by using Internet means and organizational mode innovation, which is of great significance to promote the transformation and upgrading of the logistics freight industry and improve the quality and efficiency. The planning and construction objectives of the "car-free carrier" platform envisaged by Jianfeng International Trade are: based on the influence of the peak region and the advantages of integrating qualification resources, changing the competition mode, expanding the market coverage and profit pattern, and realizing the transformation and upgrading of traditional businesses, I .e. realizing the "five" operations of PDCA closed-loop operation of supply chain system and marketing marketization, coordination of transportation capacity, customization of services, platform datalization and de-intermediation, we will continue to promote the regional logistics market from low, small, scattered and empty to resource sharing, value sharing and win-win cooperation, and finally build an integrated supply chain service system of "logistics Internet post-market finance. The relevant person in charge of the peak international trade said that the "car-free carrier" pilot qualification, for the peak international trade to change the business model, improve the quality of service.

2020

07-31

Peak International Trade Won Cotton Yarn Delivery Warehouse Qualification

On August 2, Zhengzhou Commodity Exchange issued "on the establishment of a new designated cotton yarn delivery warehouse and the announcement of the water", the peak international trading company officially obtained the Zheng Shang designated delivery warehouse qualification. According to the amendment to the cotton yarn futures business rules announced by Zheng Shang in March, the social warehouse delivery method will be introduced on the basis of retaining the original factory warehouse delivery, and will take the lead in implementing it in Shandong, Henan, Jiangsu and Zhejiang. As one of the eight new warehouse delivery units after the amendment is issued, Jianfeng International Trade can carry out cotton yarn futures delivery business from September 2019. Lanxi City, a subsidiary of Jinhua, is a "famous weaving city in China" and a national textile industry base. It has more than 1000 textile enterprises and an annual demand for cotton yarn of more than 1 million tons. After Jianfeng International Trade obtains the qualification for cotton yarn futures delivery, it can not only provide cotton yarn futures delivery sites for Lanxi cotton textile industry and upstream and downstream merchants, but also effectively serve Jinhua counties and cities, Xiaoshan, Shaoxing, Quzhou, Wenzhou and other places, and other provinces, and Fujian provinces. Since Jianfeng International Trade became a futures delivery warehouse in 2009, it has carried out four types of business of Dalian Commodity Exchange PVC, PE, PP and plywood. Cotton yarn delivery is the company's first business variety in Zhengzhou Commodity Exchange. At present, Jianfeng International Trade is actively organizing learning and training on cotton yarn business knowledge, actively expanding business channels, and understanding the actual needs of upstream and downstream industries to ensure the operation, service quality and delivery efficiency of this new business. (Huang Zhiyu)

2020

07-31

Peak International Trade Won Cotton Yarn Delivery Warehouse Qualification

2020

07-30

Peak International Trade Won Cotton Yarn Delivery Warehouse Qualification

2020

07-31

Peak International Trade Won Cotton Yarn Delivery Warehouse Qualification

2020

07-22

Peak Pharmaceuticals Ranked "Top 100 Chinese Drugs"

From July 15 to 18, the National Pharmacy Week and China Pharmaceutical Innovation and Development Conference was held in Jinan, Shandong Province. The conference released the "2018 China Pharmaceutical Industry Top 100 Series List". Zhejiang Jianfeng Pharmaceutical Co., Ltd. ranked 74th in the "TOP100 List of Chinese Pharmaceutical Enterprises. The "2018 Top 100 Series List of Chinese Pharmaceutical Industry" is divided into five sub-lists: "TOP100 List of Chinese Pharmaceutical Enterprises", "TOP100 List of Chinese Traditional Medicine Enterprises", "TOP20 List of Chinese CRO (including CDMO) Enterprises", "TOP20 List of Chinese Medical Devices (including IVD) Enterprises" and "TOP20 List of Chinese Biomedicine (including Blood Products, Vaccines, Insulin, etc.) Enterprises. The "chemical pharmaceutical enterprise" in the "TOP100 list of Chinese pharmaceutical enterprises" refers to the enterprises whose terminal sales of chemical drugs account for more than 51% of the total terminal income of the enterprises. The selection score consists of two parts, one is the innovation driving force of the enterprise, that is, the R & D comprehensive index score of R & D investment in 2018, accounting for 40% of the weight; The second is the professional promotion power of the enterprise, that is, the terminal quantitative data determined by the final selection needs of clinicians and patients in 2018, accounting for 60% of the weight; the objects participating in the selection are pharmaceutical industry enterprises registered in China (excluding subsidiaries of multinational pharmaceutical enterprises in China) and whose main business is pharmaceutical manufacturing. The convening of the conference and the release of the list have received widespread attention from the industry. Relevant leaders of the state and Shandong Province attended the meeting, chief scientist of Peak Pharmaceutical, Chinese Academy of Engineering

2020

07-31

< 1...29 30 31...61 > 跳转到页